120 filings
Page 4 of 6
8-K
40lqhiurpu oogrtv9
7 May 19
Xenon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:40pm
8-K
jhdtr62crqq4ahnsnik
25 Mar 19
Departure of Directors or Certain Officers
4:30pm
8-K
keixuxs 5dl8
13 Mar 19
Other Events
5:16pm
8-K
d8uie9x0ttezghwu
6 Mar 19
Xenon Pharmaceuticals Reports 2018 Financial Results and Provides Corporate Update
4:45pm
8-K
l2k x0gkql33c
6 Nov 18
Xenon Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
4:09pm
8-K
2is8su 7mj
13 Sep 18
Termination of a Material Definitive Agreement
12:00am
8-K
3jt vuvhunqhp
12 Sep 18
Other Events
12:00am
8-K
iq0yef
11 Sep 18
Xenon Enters into Agreement to Buy Out Milestones and Royalties Related to its XEN1101 Program
12:00am
8-K
rmycyai0p
6 Sep 18
Xenon Expands Ion Channel Neurology Pipeline with Addition of XEN496, a “Phase 3 Ready” Potassium Channel Modulator for the Treatment of Epilepsy
12:00am
8-K
fak4t5 ql019edi
29 Aug 18
Xenon Announces Positive XEN1101 Pharmacodynamic Data from Phase 1b TMS Study
12:00am
8-K
u4okibnv
7 Aug 18
Xenon Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
4:51pm
8-K
3r1x5 r1qzw
7 Aug 18
Entry into a Material Definitive Agreement
12:00am
8-K
a821clx1st
12 Jul 18
Entry into a Material Definitive Agreement
6:05am
8-K
fukehhjy3dl3t mqcn
3 Jul 18
Other Events
3:35pm
8-K
06uyd
13 Jun 18
Entry into a Material Definitive Agreement
12:00am
8-K
z3bragrggz2n itw
5 Jun 18
Submission of Matters to a Vote of Security Holders
4:13pm
8-K
n7xgt2 udvpb
15 May 18
Xenon Presents XEN901 Phase 1 Clinical Update and Supporting Pre-clinical Data at 14th Eilat Conference
7:23am
8-K
1c1bcy9u
8 May 18
Entry into a Material Definitive Agreement
4:55pm
8-K
7ds9c1f s5hcdd
8 May 18
Xenon Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
t93rwqtk xbt6
28 Mar 18
Entry into a Material Definitive Agreement
12:00am